GHP Funds

SVP I

SVP I, the debut fund for the firm, closed in December 2002 and invested with four highly successful leveraged buyout funds. SVP I is diversified by sector and geography.

Learn More
SVP II

SVP II is a leveraged buyout fund of funds which closed in December 2006. SVP II represents a continuation of the successful strategy utilized by the predecessor fund, primarily investing with large, top tier LBO and growth equity firms. SVP II is diversified by sector and geography.

Learn More
SVP RE I

SVP Real Estate I, LP ("SVP RE I"), closed in February 2008, is a private real estate fund of funds. As with SVP I & II, SVP RE I received allocations with historically successful, highly sought after underlying fund managers who pursue compelling investment strategies. The fund is diversified by sector (Office, Hotel, Industrial/Warehouse, Retail and Residential) and geography (U.S., Europe, and Asia/Pacific).

Learn More
GHP COF

The GHP Credit Opportunity Fund (“GHP COF”) is a fund of alternative credit and distressed debt funds that is being raised and invested to pursue two specific investment themes: (1) the de-leveraging of European Banks, and (2) the potential for a distressed cycle in U.S. High Yield Credit. GHP COF will pursue complex liquid and illiquid credit opportunities in the U.S. and Europe.

Learn More

Monthly Archives: October 2018

Marijuana stocks to watch: MedMen turns a vision into reality with largest-ever U.S. pot merger

Posted on by Granite Hall Partners

MedMen’s stock has soared 61% in a week since the company announced a $682 million deal to buy PharmCann Getty Images MedMen Enterprises Inc. co-founder Adam Bierman believes the company’s $682 million acquisition of PharmCann last week marked the culmination of the U.S. cannabis industry’s transformation from vision to reality. The deal, the biggest ever […]


MedMen to Acquire PharmaCann for $682 Million in Stock

Posted on by Granite Hall Partners

MedMen Doubles Market Reach with Acquisition of PharmaCann MedMen to acquire PharmaCann in all-stock transaction valued at US$682 million, the largest acquisition transaction in U.S. cannabis history. The acquisition doubles the number of states where MedMen has licenses to 12. The combined addressable market in these 12 states accounts for over 50 percent of the […]